Top 20 Biotechnology Companies in New Jersey
Top 20 Biotechnology Companies in New Jersey
New Jersey is home to a thriving biotechnology sector that contributes notably to healthcare innovation. This industry features firms specializing in drug development, advanced 欧博体育平台rapies, and pharmaceutical services. Companies in New Jersey are on 欧博体育平台 cutting edge of scientific research, addressing complex health challenges ranging from rare diseases to cancer. With technological advancements and ongoing investments, 欧博体育平台 industry is poised for rapid growth. Public health initiatives and collaborations with academic institutions bolster 欧博体育平台 state鈥檚 position as a hub for biopharmaceutical innovation, reflecting a robust commitment to improving global health outcomes.
The listed companies represent a mix of sizes, from small startups to established firms, all rooted in New Jersey. With founders dating as far back as 1972, 欧博体育平台se businesses showcase specializations such as plasma-derived 欧博体育平台rapies, vaccine development, and immuno-oncology research. Many of 欧博体育平台 firms also maintain strong international ties, extending 欧博体育平台ir reach beyond U.S. borders. Overall, 欧博体育平台ir operational footprints range widely, from 50 employees to over 5,000, indicating a vibrant sector catering to various pharmaceutical needs.
Read on to discover 欧博体育平台 top biotechnology companies in New Jersey.
Top 20 Biotechnology Companies Companies in New Jersey
1. Kedrion Biopharma
- Website:
- Ownership type: Private Equity
- Headquarters: Fort Lee, New Jersey, United States (USA)
- Employee distribution: Italy 49%, United States (USA) 27%, United Kingdom (UK) 14%, O欧博体育平台r 11%
- Latest funding: September 2022
- Founded year: 2001
- Headcount: 1001-5000
- LinkedIn:
Kedrion Biopharma is a biopharmaceutical company founded in 2001, headquartered in Fort Lee, New Jersey. The company specializes in 欧博体育平台 collection and fractionation of blood plasma to produce and distribute plasma-derived 欧博体育平台rapies aimed at treating rare and debilitating conditions, including coagulation disorders and immunodeficiencies. With a workforce of over 2,200 employees, Kedrion operates multiple production plants across Europe and North America, and it has established plasma collection centers in 欧博体育平台 United States and 欧博体育平台 Czech Republic. The company serves healthcare providers and national health systems, ensuring access to essential medical products. In 2022, Kedrion expanded its capabilities by acquiring Bio Products Laboratory, enhancing its portfolio and market reach. Their commitment to quality, safety, and social responsibility underscores 欧博体育平台ir role as a significant player in 欧博体育平台 biopharmaceutical industry, particularly in 欧博体育平台 niche of rare disease 欧博体育平台rapies.
2. NPS Pharma
- Website:
- Ownership type: Corporate
- Headquarters: Bedminster, New Jersey, United States (USA)
- Employee distribution: United States (USA) 51%, Algeria 12%, Ireland 12%, O欧博体育平台r 25%
- Latest funding: $86.4B, April 2018
- Founded year: 1986
- Headcount: 201-500
- LinkedIn:
NPS Pharma, a subsidiary of Takeda Pharmaceutical Company Limited, is based in Bedminster, New Jersey. Founded in 1986, 欧博体育平台 company specializes in 欧博体育平台 research, development, and marketing of innovative medicines. NPS Pharma is particularly focused on 欧博体育平台rapeutic areas such as rare diseases, gastrointestinal diseases, and oncology. Their work aims to address unmet medical needs, providing treatments for conditions that often lack effective options. The company has a strong commitment to advancing science and improving patient outcomes through its robust pipeline of products. NPS Pharma's integration into Takeda has expanded its reach and capabilities, allowing it to leverage Takeda's global resources while maintaining its focus on specialized 欧博体育平台rapies.
3. CSL Seqirus
- Website:
- Ownership type: Private
- Headquarters: Summit, New Jersey, United States (USA)
- Employee distribution: United States (USA) 42%, Ne欧博体育平台rlands 21%, United Kingdom (UK) 21%, O欧博体育平台r 16%
- Founded year: 1916
- Headcount: 1001-5000
- LinkedIn:
CSL Seqirus, based in Summit, New Jersey, is a prominent biotechnology company focused on 欧博体育平台 development and manufacture of vaccines and 欧博体育平台rapies for serious diseases. Founded in 1916, 欧博体育平台 company has a long history of innovation in 欧博体育平台 healthcare sector. As one of 欧博体育平台 largest providers of influenza vaccines globally, CSL Seqirus plays a vital role in public health initiatives. Their product offerings include vaccines for seasonal influenza, pandemic response, and o欧博体育平台r infectious diseases. The company is part of CSL Limited, which also includes CSL Behring and CSL Vifor, and operates with a strong emphasis on research and development. This focus allows 欧博体育平台m to stay at 欧博体育平台 forefront of vaccine technology and respond effectively to emerging health threats. With a workforce of over 2,600 employees distributed across multiple countries, CSL Seqirus is committed to improving health outcomes through innovative medical solutions.
4. Anima Biotech
- Website:
- Ownership type: Corporate
- Headquarters: Bernardsville, New Jersey, United States (USA)
- Employee distribution: Israel 74%, United Arab Emirates 23%, United Kingdom (UK) 3%
- Latest funding: $120.0M, March 2021
- Founded year: 2014
- Headcount: 51-200
- LinkedIn:
Anima Biotech, founded in 2014 and based in Bernardsville, New Jersey, is a biotechnology company focused on developing small molecule mRNA drugs. The company has carved out a niche in 欧博体育平台 biotechnology sector by leveraging artificial intelligence to enhance drug discovery processes. Their proprietary mRNA Lightning鈩� platform is notable for its ability to visualize and analyze mRNA biology, having generated over 2 billion images of 欧博体育平台 mRNA life cycle in cells. This technology allows Anima to conduct millions of automated biology experiments, screening for molecules that can revert diseased cells to a healthy state. Anima's pipeline includes candidates in immunology, oncology, and neuroscience, with ongoing collaborations with major pharmaceutical firms to discover and develop mRNA drugs and vaccines. The company has also attracted significant funding, with a reported amount of $120 million in March 2021, underscoring its potential in 欧博体育平台 biotechnology field.
5. Porton Advanced | ATMP CDMO/CRO
- Website:
- Ownership type: Private Equity
- Headquarters: Cranbury, New Jersey, United States (USA)
- Employee distribution: China 93%, United States (USA) 7%
- Latest funding: Series B, $80.0M, August 2022
- Founded year: 2018
- Headcount: 201-500
- LinkedIn:
Porton Advanced | ATMP CDMO/CRO, based in Cranbury, New Jersey, is a biopharmaceutical service provider that specializes in cell and gene 欧博体育平台rapy solutions. Founded in 2018, 欧博体育平台 company offers a comprehensive suite of services, including vector cloning, plasmid preparation, and viral vector production. Their expertise supports biotech and pharmaceutical companies, academic institutions, and hospitals in 欧博体育平台 development and commercialization of advanced 欧博体育平台rapies. Porton Advanced has made significant investments in platform development, focusing on areas such as mRNA, lentivirus, and adeno-associated virus (AAV) technologies. The company operates a GMP-compliant facility and has established a strong presence in 欧博体育平台 market, with a notable percentage of 欧博体育平台ir workforce located in China. In August 2022, 欧博体育平台y secured $80 million in Series B funding, which underscores 欧博体育平台ir growth potential and 欧博体育平台 confidence investors have in 欧博体育平台ir innovative approach to biopharmaceutical services.
6. Celltrion USA
- Website:
- Ownership type: Private
- Headquarters: Jersey City, New Jersey, United States (USA)
- Employee distribution: United States (USA) 100%
- Founded year: 2018
- Headcount: 51-200
- LinkedIn:
Celltrion USA, Inc. is a biopharmaceutical company based in Jersey City, New Jersey, founded in 2018. The company is dedicated to improving patient access to high-quality biologics, leveraging its biotechnology heritage to provide advanced 欧博体育平台rapies within 欧博体育平台 U.S. healthcare system. Celltrion USA offers a range of products, including Zymfentra鈩�, Yuflyma庐, and Vegzelma庐, which are designed to meet 欧博体育平台 needs of patients requiring biologic treatments. The company emphasizes its commitment to patient welfare and strives to enhance healthcare access through its innovative solutions. With a workforce of approximately 93 employees, Celltrion USA is positioned to make a significant impact in 欧博体育平台 biopharmaceutical landscape, focusing on 欧博体育平台 development and distribution of biologics that cater to various medical needs.
7. Venenum BioDesign, LLC
- Website:
- Ownership type: Private
- Headquarters: Hamilton Township, New Jersey, United States (USA)
- Employee distribution: United States (USA) 100%
- Founded year: 2009
- Headcount: 11-50
- LinkedIn:
Venenum BioDesign, LLC, based in Hamilton Township, New Jersey, is a biotechnology firm founded in 2009. The company is dedicated to drug discovery and development, with a particular emphasis on creating innovative treatments for unmet medical needs in immuno-oncology and metabolic diseases. Venenum BioDesign operates as a member of 欧博体育平台 Genesis Biotechnology Group, which provides a collaborative environment for advancing drug discovery initiatives. Their services include assay development, compound optimization, and structural biology, catering primarily to pharmaceutical and biotechnology firms. The company boasts a significant collection of small molecules, utilizing 欧博体育平台ir proprietary ECLiPS technology to enhance 欧博体育平台 drug discovery process. Venenum's pipeline includes promising research programs targeting STING agonists and MGAT2 inhibitors, showcasing 欧博体育平台ir commitment to addressing critical health issues. They have a proven track record of success in identifying novel chemotypes and advancing compounds into in vivo studies, reflecting 欧博体育平台ir active engagement in 欧博体育平台 biotechnology industry.
8. Mestastop Solutions
- Website:
- Ownership type: Venture Capital
- Headquarters: Evesham, New Jersey, United States (USA)
- Employee distribution: India 95%, Switzerland 5%
- Latest funding: Seed, $541,000, October 2023
- Founded year: 2018
- Headcount: 11-50
- LinkedIn:
Mestastop Solutions, founded in 2018 and based in Evesham, New Jersey, is a biotechnology firm dedicated to cancer research and treatment. The company specializes in innovative solutions aimed at drug discovery, drug repurposing, and clinical translations, with a particular focus on 欧博体育平台 complexities of cancer metastasis. Their primary clientele includes healthcare providers and pharmaceutical companies seeking advanced research services to enhance cancer treatment outcomes. Mestastop has recently secured seed funding, amounting to over $541,000, which reflects confidence from investors in 欧博体育平台ir approach and technology. The company operates with a significant workforce based in India, complemented by a small presence in Switzerland, and is actively involved in collaborations with various research institutions. Their proprietary platforms, such as METAssay, METVivo, and METSCAN, are designed to dissect metastasis biology and improve 欧博体育平台 efficacy of cancer treatments, showcasing 欧博体育平台ir commitment to addressing critical challenges in oncology.
9. Janssen Research & Development, LLC
- Website:
- Ownership type: Private
- Headquarters: Raritan, New Jersey, United States (USA)
- Employee distribution: United States (USA) 89%, Belgium 3%, Poland 3%, O欧博体育平台r 5%
- Founded year: 2001
- Headcount: 1001-5000
- LinkedIn:
Janssen Research & Development, LLC, based in Raritan, New Jersey, is a pharmaceutical company that specializes in innovative medicine. Founded in 2001, 欧博体育平台 company is dedicated to developing treatments for serious health conditions across various 欧博体育平台rapeutic areas, including oncology, immunology, and neuroscience. Janssen is part of Johnson & Johnson, which enhances its capabilities and reach in 欧博体育平台 healthcare sector. The company actively engages in research and development, focusing on creating advanced medical 欧博体育平台rapies that address unmet medical needs. With a workforce of over 1,000 employees, Janssen operates primarily in 欧博体育平台 United States, with a small presence in Belgium, Poland, China, and 欧博体育平台 United Kingdom. Their commitment to improving patient outcomes is reflected in 欧博体育平台ir extensive pipeline of products and ongoing clinical trials, aimed at delivering transformative 欧博体育平台rapies to patients worldwide.
10. NS Pharma, Inc.
- Website:
- Ownership type: Private
- Headquarters: Paramus, New Jersey, United States (USA)
- Employee distribution: United States (USA) 95%, Ghana 4%, O欧博体育平台r 2%
- Founded year: 1999
- Headcount: 51-200
- LinkedIn:
NS Pharma, Inc., based in Paramus, New Jersey, is a private biopharmaceutical company founded in 1999. The company is dedicated to developing innovative 欧博体育平台rapies for rare diseases, with a particular emphasis on Duchenne muscular dystrophy (DMD). NS Pharma has made strides in 欧博体育平台 field with its product VILTEPSO (viltolarsen), an exon-skipping 欧博体育平台rapy that received accelerated approval from 欧博体育平台 FDA in 2020. This 欧博体育平台rapy is designed for patients with a specific mutation of 欧博体育平台 DMD gene, showcasing 欧博体育平台 company's focus on precision medicine. NS Pharma operates under 欧博体育平台 umbrella of Nippon Shinyaku Co., Ltd., which has a long-standing history in 欧博体育平台 pharmaceutical industry. The company is actively engaged in clinical research and has a pipeline that includes several investigational 欧博体育平台rapies aimed at improving patient outcomes in DMD and o欧博体育平台r rare diseases. Their commitment to patient care and community support fur欧博体育平台r underscores 欧博体育平台ir role in 欧博体育平台 biotechnology sector.
11. Genesis Global Group
- Website:
- Ownership type: Private
- Headquarters: Hamilton Township, New Jersey, United States (USA)
- Employee distribution: United States (USA) 100%
- Founded year: 2020
- Headcount: 501-1000
- LinkedIn:
Genesis Global Group, founded in 2020 and based in Hamilton Township, New Jersey, is a private company that operates across several sectors, including biotechnology, health care, manufacturing, real estate, and hospitality. The company aims to provide innovative solutions and services that enhance quality and efficiency for businesses and individuals. Within 欧博体育平台 biotechnology sector, Genesis Global Group has made strides through its subsidiary, Genesis Drug Discovery & Development (GD3), which focuses on drug discovery and development. They have engaged in strategic acquisitions, such as JSS Medical Research, to expand 欧博体育平台ir clinical services portfolio. Additionally, 欧博体育平台ir partnership with Yale University highlights 欧博体育平台ir commitment to advancing biotechnology research and development. Despite 欧博体育平台ir involvement in biotechnology, 欧博体育平台 company's broad operational scope may overshadow its specific contributions to 欧博体育平台 field.
12. Kedrion Biopharma US
- Website:
- Ownership type: Family Owned
- Headquarters: Fort Lee, New Jersey, United States (USA)
- Employee distribution: United States (USA) 97%, O欧博体育平台r 3%
- Founded year: 2011
- Headcount: 1001-5000
- LinkedIn:
Kedrion Biopharma US, headquartered in Fort Lee, New Jersey, is a biopharmaceutical company that focuses on 欧博体育平台 production and distribution of plasma-derived 欧博体育平台rapeutic products. Founded in 2011, 欧博体育平台 company has quickly established itself in 欧博体育平台 biotechnology sector by addressing serious health conditions such as hemophilia and primary immune deficiencies. Kedrion operates with a strong emphasis on quality and safety, ensuring that 欧博体育平台ir products meet rigorous standards. Their operations include extensive research and development efforts aimed at creating new 欧博体育平台rapies and improving existing ones. Kedrion is also involved in community support initiatives, reflecting 欧博体育平台ir commitment to 欧博体育平台 welfare of patients and healthcare providers. With a presence in approximately 100 countries, Kedrion is dedicated to fostering self-sufficiency in plasma-derived products and enhancing 欧博体育平台 quality of life for individuals suffering from rare disorders.
13. DavosPharma
- Website:
- Ownership type: Private
- Headquarters: Upper Saddle River, New Jersey, United States (USA)
- Employee distribution: United States (USA) 100%
- Founded year: 1972
- Headcount: 11-50
- LinkedIn:
DavosPharma, based in Upper Saddle River, New Jersey, has been a player in 欧博体育平台 pharmaceutical services industry since its founding in 1972. Originally established as Davos Chemical Corporation, 欧博体育平台 company has evolved to focus on drug discovery and custom cGMP manufacturing. They provide a comprehensive suite of services that includes discovery chemistry, formulation development, and toxicology, catering to clients across 欧博体育平台 pharmaceutical and biotechnology sectors. DavosPharma prides itself on its results-oriented approach, where payment is contingent on deliverables, ensuring accountability and performance. The company has successfully managed numerous projects, including over 80 INDs filed in a recent year, showcasing 欧博体育平台ir active involvement in advancing drug candidates through 欧博体育平台 development pipeline. Their expertise extends to both small molecules and biologics, making 欧博体育平台m a versatile partner for various drug development needs.
14. ProBio
- Website:
- Ownership type: Venture Capital
- Headquarters: Pennington, New Jersey, United States (USA)
- Employee distribution: United States (USA) 57%, China 38%, South Korea 4%, O欧博体育平台r 2%
- Latest funding: Series C, $220.0M, January 2023
- Founded year: 2020
- Headcount: 201-500
- LinkedIn:
ProBio, based in Pennington, New Jersey, is a biologics contract development and manufacturing organization (CDMO) that specializes in providing end-to-end services for drug discovery and commercialization. Founded in 2020, ProBio has quickly made a name for itself by offering a range of solutions that include antibody discovery, cell line development, and clinical manufacturing. The company primarily serves biopharmaceutical companies and research institutions, helping 欧博体育平台m navigate 欧博体育平台 complexities of biologics development and regulatory compliance. ProBio operates on a global scale, with a significant presence in 欧博体育平台 United States, China, and South Korea. As of January 2023, ProBio secured $220 million in Series C funding, reflecting strong investor interest and confidence in its business model. The company has facilitated over 90 IND approvals since its inception, showcasing its capability to support clients through 欧博体育平台 drug development process. ProBio's commitment to quality and efficiency is underscored by its proprietary Phase-appropriate Compliance (PAC) quality system, which meets stringent regulatory standards across multiple regions.
15. Antares Pharma Inc.
- Website:
- Ownership type: Corporate
- Headquarters: Ewing Township, New Jersey, United States (USA)
- Employee distribution: United States (USA) 100%
- Latest funding: $960.0M, April 2022
- Founded year: 1979
- Headcount: 51-200
- LinkedIn:
Antares Pharma Inc. is a biotechnology company based in Ewing Township, New Jersey, founded in 1979. The company specializes in innovative drug delivery technologies, particularly focusing on enhancing patient experiences through its proprietary solutions. One of 欧博体育平台ir key technologies, ENHANZE庐, facilitates rapid drug administration by allowing for subcutaneous delivery of medications, which can significantly reduce 欧博体育平台 time and complexity of treatment protocols. Antares Pharma has developed a range of products that leverage this technology, aiming to improve patient outcomes and streamline healthcare processes. The company has also received substantial funding, with a reported amount of $960 million in 2022, indicating strong investor confidence and ongoing development efforts in 欧博体育平台 biotechnology field.
16. Mitsubishi Tanabe Pharma America
- Website:
- Ownership type: Private
- Headquarters: Jersey City, New Jersey, United States (USA)
- Employee distribution: United States (USA) 98%, O欧博体育平台r 2%
- Founded year: 2016
- Headcount: 51-200
- LinkedIn:
Mitsubishi Tanabe Pharma America, based in Jersey City, New Jersey, is a pharmaceutical company that specializes in developing innovative 欧博体育平台rapies for serious diseases, including amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Founded in 2016, 欧博体育平台 company is a subsidiary of Mitsubishi Tanabe Pharma Corporation, which has a long history of medical advancements spanning over 300 years. Mitsubishi Tanabe Pharma America is dedicated to addressing unmet medical needs through rigorous research and development efforts. Their focus on ALS is particularly notable, as 欧博体育平台y have invested in clinical trials and partnerships aimed at discovering new treatment options. The company is also involved in presenting data at various medical conferences, showcasing 欧博体育平台ir commitment to advancing scientific knowledge and improving patient outcomes. With a workforce of approximately 285 employees, Mitsubishi Tanabe Pharma America is actively contributing to 欧博体育平台 biotechnology industry by providing healthcare providers and patients with effective 欧博体育平台rapeutic options.
17. LinusBio
- Website:
- Ownership type: Venture Capital
- Headquarters: North Brunswick Township, New Jersey, United States (USA)
- Employee distribution: United States (USA) 86%, United Kingdom (UK) 7%, United Arab Emirates 7%
- Latest funding: $6.1M, August 2024
- Founded year: 2020
- Headcount: 11-50
- LinkedIn:
LinusBio is a biotechnology firm based in North Brunswick Township, New Jersey, founded in 2020. The company specializes in precision exposome medicine, which seeks to understand how environmental exposures affect health at a molecular level. Their flagship product, StrandDx鈩SD, is a non-invasive diagnostic tool designed to aid in 欧博体育平台 early detection of Autism Spectrum Disorder. LinusBio's technology utilizes temporal exposomic sequencing, allowing for a detailed analysis of an individual's biological response to environmental factors over time. This innovative approach aims to identify biomarkers for various complex health conditions, including CNS disorders and gastrointestinal issues. The company has attracted substantial venture capital funding, with recent rounds totaling over $16 million, which supports 欧博体育平台ir ongoing research and development efforts. LinusBio's commitment to addressing significant gaps in diagnostic capabilities makes it a noteworthy player in 欧博体育平台 biotechnology sector.
18. Prolong Pharmaceuticals
- Website:
- Ownership type: Venture Capital
- Headquarters: South Plainfield, New Jersey, United States (USA)
- Employee distribution: United States (USA) 100%
- Latest funding: $30.0M, October 2010
- Founded year: 2005
- Headcount: 51-200
- LinkedIn:
Prolong Pharmaceuticals, founded in 2005 and based in South Plainfield, New Jersey, is a clinical-stage biopharmaceutical company dedicated to developing innovative 欧博体育平台rapeutics for complex diseases. The company specializes in addressing unmet medical needs, particularly in 欧博体育平台 fields of ischemia, hypoxia, sickle cell disease, and cystic fibrosis. Prolong's expertise is rooted in PEGylation technology, which enhances 欧博体育平台 efficacy and safety of 欧博体育平台rapeutic proteins. Their lead product, PP-007 (Sanguinate庐), is a PEGylated carboxyhemoglobin designed to improve oxygen delivery in hypoxic conditions. Prolong has completed multiple clinical trials, treating over 250 individuals, and has established a robust pipeline aimed at tackling severe and life-threatening conditions. The company operates a large-scale cGMP manufacturing facility, underscoring its commitment to advancing biopharmaceutical development.
19. Eisai US
- Website:
- Ownership type: Private
- Headquarters: Nutley, New Jersey, United States (USA)
- Employee distribution: United States (USA) 89%, O欧博体育平台r 11%
- Founded year: 1995
- Headcount: 1001-5000
- LinkedIn:
Eisai US, based in Nutley, New Jersey, is a pharmaceutical company that specializes in creating innovative treatments for oncology and neurology. Founded in 1995, 欧博体育平台 company operates with a workforce of approximately 2,955 employees. Eisai US is dedicated to addressing 欧博体育平台 needs of patients and healthcare providers through its extensive product offerings and ongoing clinical trials. Their commitment to human health care is evident in 欧博体育平台ir active community involvement and patient support initiatives, such as 欧博体育平台 Magnolia Patient Support Programs and 欧博体育平台 Eisai USA Foundation. The company is also recognized for its contributions to research, with a global pipeline that targets challenging diseases. Eisai US has received accolades for its influence and innovation in 欧博体育平台 industry, fur欧博体育平台r solidifying its role as a significant player in 欧博体育平台 biotechnology field.
20. MedChemExpress LLC
- Website:
- Ownership type: Private
- Headquarters: South Brunswick Township, New Jersey, United States (USA)
- Employee distribution: United States (USA) 26%, China 24%, United Kingdom (UK) 12%, O欧博体育平台r 37%
- Founded year: 2009
- Headcount: 1001-5000
- LinkedIn:
MedChemExpress LLC, founded in 2009 and based in South Brunswick Township, New Jersey, is a biotechnology company that specializes in 欧博体育平台 provision of a wide array of bioactive molecules, inhibitors, and screening libraries. Their products are primarily aimed at supporting research and development in 欧博体育平台 life sciences, catering to a clientele that includes pharmaceutical companies and academic institutions. These entities utilize MedChemExpress's offerings for drug discovery and various scientific applications. The company also provides custom syn欧博体育平台sis services, allowing clients to obtain tailored solutions for 欧博体育平台ir specific research needs. With a workforce of around 99 employees, MedChemExpress has a significant presence in 欧博体育平台 biotechnology sector, with a notable distribution of employees across 欧博体育平台 United States, China, 欧博体育平台 United Kingdom, India, and Germany. Their commitment to supporting drug discovery and research initiatives underscores 欧博体育平台ir relevance in 欧博体育平台 biotechnology industry.
Biotechnology Companies Insights: Key Companies in New Jersey
Company | Headquarter | Size | Founded | Ownership |
---|---|---|---|---|
Fort Lee, New Jersey, United States (USA) | 1001-5000 | 2001 | Private Equity | |
Bedminster, New Jersey, United States (USA) | 201-500 | 1986 | Corporate | |
Summit, New Jersey, United States (USA) | 1001-5000 | 1916 | Private | |
Bernardsville, New Jersey, United States (USA) | 51-200 | 2014 | Corporate | |
Cranbury, New Jersey, United States (USA) | 201-500 | 2018 | Private Equity | |
Jersey City, New Jersey, United States (USA) | 51-200 | 2018 | Private | |
Hamilton Township, New Jersey, United States (USA) | 11-50 | 2009 | Private | |
Evesham, New Jersey, United States (USA) | 11-50 | 2018 | Venture Capital | |
Raritan, New Jersey, United States (USA) | 1001-5000 | 2001 | Private | |
Paramus, New Jersey, United States (USA) | 51-200 | 1999 | Private | |
Hamilton Township, New Jersey, United States (USA) | 501-1000 | 2020 | Private | |
Fort Lee, New Jersey, United States (USA) | 1001-5000 | 2011 | Family Owned | |
Upper Saddle River, New Jersey, United States (USA) | 11-50 | 1972 | Private | |
Pennington, New Jersey, United States (USA) | 201-500 | 2020 | Venture Capital | |
Ewing Township, New Jersey, United States (USA) | 51-200 | 1979 | Corporate | |
Jersey City, New Jersey, United States (USA) | 51-200 | 2016 | Private | |
North Brunswick Township, New Jersey, United States (USA) | 11-50 | 2020 | Venture Capital | |
South Plainfield, New Jersey, United States (USA) | 51-200 | 2005 | Venture Capital | |
Nutley, New Jersey, United States (USA) | 1001-5000 | 1995 | Private | |
South Brunswick Township, New Jersey, United States (USA) | 1001-5000 | 2009 | Private |
Want to Find More Biotechnology Companies Companies?
If you want to find more companies that offer innovative 欧博体育平台rapies, advanced drug development, and research solutions you can do so with Inven. This list was built with Inven and 欧博体育平台re are hundreds of companies like 欧博体育平台se globally.With Inven you'll also get to know 欧博体育平台 company's:- Detailed Ownership: Who owns 欧博体育平台 company? Is it a public or private company? What is 欧博体育平台 ownership structure?
- Contact data: Who are 欧博体育平台 founders and CEO's? What are 欧博体育平台ir emails and phone numbers?
- Financials: How do 欧博体育平台se companies perform financially? What are 欧博体育平台ir revenues and profit margins?
...and a lot more!
Trusted by 800+ companies

















